에 대한 최신 뉴스 Akero Therapeutics (NASDAQ:AKRO) 주식

Akero Therapeutics

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Equities

Mid Cap

News

Movers

Trading Ideas

AKRO

Brighthouse Financial, Inc. - Common Stock

Hims & Hers Health, Inc. Class A Common Stock

HIMS

SGRY

VIAV

이 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 아케로 테라퓨틱스(NASDAQ:AKRO)의 주가는 회사가 에프룩시퍼민(Efruxifermin)에 대한 SYMMETRY 2B상 연구의 96주차 예비 결과를 보고한 후 주가는 106.57% 급등했다. 몇몇 애널리스트들이 목표 주가를 상향 조정했다.

아케로 테라퓨틱스, 브링커 인터내셔널, 비아비 등 지난주 최대 상승한 중형주 (1월 27일-1월 31일)

Akero Therapeutics Inc

Akropolis

Kraft Heinz's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NYSE">KHC</a>) short percent of float has risen 11.14% since its last report. The company recently reported that it has 39.76 million shares sold short, which is 4.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Kraft Heinz Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741278641_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kraft Heinz has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Kraft Heinz's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Kraft Heinz's peer group average for short interest as a percentage of float is 6.27%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Kraft Heinz's Recent Short Interest

Bloom Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) short percent of float has risen 4.77% since its last report. The company recently reported that it has 45.53 million shares sold short, which is 31.85% of all regular shares that are available for trading. Based on its trading volume, it would take traders 10.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Bloom Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741278636_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Bloom Energy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Bloom Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Bloom Energy's peer group average for short interest as a percentage of float is 9.39%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Bloom Energy?

Waters's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) short percent of float has fallen 18.89% since its last report. The company recently reported that it has 1.30 million shares sold short, which is 2.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.54 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Waters Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741278631_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Waters has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Waters's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Waters's peer group average for short interest as a percentage of float is 5.72%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Waters?

Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) has outperformed the market over the past 10 years by 36.71% on an annualized basis producing an average annual return of 47.69%. Currently, Shopify has a market capitalization of $139.37 billion. 
Buying $100 In SHOP: If an investor had bought $100 of SHOP stock 10 years ago, it would be worth $4,948.97 today based on a price of $107.64 for SHOP at the time of writing.
<h3>Shopify's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741278626_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SHOP

$100 Invested In Shopify 10 Years Ago Would Be Worth This Much Today

WIIM

Mistras Group shares are trading higher after the company reported better-than-expected Q4 financial results.

BWS Financial analyst Hamed Khorsand maintains Net Lease Office (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLOP#NYSE">NLOP</a>) with a Buy and maintains $46 price target.

Price Target

Analyst Ratings

NLOP

BWS Financial Maintains Buy on Net Lease Office, Maintains $46 Price Target

Zscaler Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) stock gained after the company reported better-than-expected <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44153144/zscaler-shares-gain-after-q2-results-heres-why" rel="noreferrer noopener">second-quarter financial results</a> and issued third-quarter adjusted EPS guidance above estimates.
Zscaler reported quarterly earnings of&nbsp;78&nbsp;cents per share, which beat the analyst consensus estimate of&nbsp;69&nbsp;cents. Quarterly revenue was&nbsp;$647.9 million (up from $525 million a year ago),&nbsp;which beat the analyst consensus estimate of&nbsp;$635.56 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/03/44163030/chatgpt-parent-openais-specialized-ai-agents-could-cost-up-to-20-thousand-per-month-report" rel="noreferrer noopener">ChatGPT Parent OpenAI&#8217;s Specialized AI Agents Could Cost Up To $20 Thousand Per Month: report</a>
Zscaler expects third-quarter revenue of $665 million to $667 million, versus the $667.37 million estimate, and EPS of 75 cents to 76 cents per share, versus the 74 cent estimate.
Rosenblatt analyst Catharine Trebnick upgraded Zscaler from Neutral to Buy and raised the <a href="https://www.benzinga.com/quote/ZS/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $190 to $235</a>.
This upgrade is driven by Trebnick&#8217;s increased confidence in Zscaler&#8217;s ability to sustain strong growth based on key factors. The analyst marginally increased her revenue forecasts for fiscal 2025 and 2026, reflecting a belief in the company&#8217;s improved sales capacity, broader platform adoption and potential to capture legacy firewall refresh initiatives. Trebnick also observed improvements in Zscaler&#8217;s GTM motions and sales execution, which are contributing to stronger performance.
The rerating reflects demonstrable performance improvements. Zscaler&#8217;s latest results exceeded expectations, driven by improved billing growth and margin expansion.
Improved marketing (Zero Trust Everywhere) and sales productivity drive more significant deals and upsells.
Calculated billings of $743 million rose 18%, beating Street estimates by $23 million, fueled by 25% growth in unscheduled billings.
This performance prompted management to raise the fiscal 2025 billings outlook, a clear signal of the company&#8217;s continued confidence in the future.
Furthermore, new products, including ZDX, Zero Trust Cloud Workload and Zero Trust Branch, are gaining traction and expected to generate 25% of total revenue at year-end.
The combined improvements in GTM motion, sales productivity, and broader platform momentum led the analyst to note the company can sustain durable growth.
Trebnick projected third-quarter revenue of $666.6 million and EPS of $0.75.
Price Action: ZS stock is up 6.95% at $210.33 at last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44164458/jdcom-q4-earnings-double-digit-growth-retail-and-logistics-surge-hikes-dividend-to-100-per-ads" target="_blank" rel="noreferrer noopener">China&#8217;s JD.com Q4 Retail Revenue And Margin Growth Impress, Hikes Annual Dividend</a></li>
</ul>

Upgrades

Zscaler Gains Analyst Upgrade As Strong Billing Growth And Zero Trust Adoption Fuel Confidence

Telemedicine operator Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) has entered a pharmacy integration agreement with Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) LillyDirect, a direct-to-consumer pharmacy partner, to streamline access to Zepbound (tirzepatide) for members of Teladoc's Comprehensive <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">Weight Care Program</a>.
Last year, Eli Lilly&nbsp;announced a&nbsp;new&nbsp;website allowing patients to get a prescription for weight loss through a telehealth provider,&nbsp;<a target="_blank" href="https://www.benzinga.com/top-stories/24/05/38798101/pfizer-follows-eli-lillys-footsteps-to-sell-medicines-directly-to-patients" rel="noreferrer noopener">marking an industry first</a>.
The collaboration aims to provide affordable and safe options for individuals without insurance coverage for GLP-1 medications <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44164208/teladoc-health-adds-glp-1-self-pay-option-to-comprehensive-weight-care" rel="noreferrer noopener">used for obesity treatment</a>.
Under the agreement, eligible Teladoc Health members prescribed Zepbound by their provider will have the medication delivered directly to their homes via LillyDirect's digital healthcare platform.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42970274/teladoc-shares-surge-as-amazon-partnership-fuels-push-for-consumer-centric-healthcare" rel="noreferrer noopener">Teladoc Stock Gains As Amazon Partnership Fuels Push for Consumer-Centric Healthcare</a>
Teladoc's Comprehensive Weight Care and Primary360 teams will have full visibility into each stage of the fulfillment process, including dispensing, shipping, delivery, and refills.
Beyond medication access, Teladoc's Comprehensive Weight Care Program offers a multi-disciplinary approach to obesity management. Members receive support from licensed clinicians with specialized training in obesity medicine, registered dietitians, and health coaches.
Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>)&nbsp;recently introduced&nbsp;NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44143391/novo-nordisk-boosts-wegovy-access-with-lower-pricing-and-home-delivery" rel="noreferrer noopener">cash-paying patients</a>.
In February, Teladoc reported fourth-quarter revenue&nbsp;of $640.5 million, down 3% year over year, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43989576/teladoc-health-reports-full-year-and-fourth-quarter-2024-results" rel="noreferrer noopener">consensus estimates</a>.
Price Action: TDOC stock is up 8.02% at $9.75 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/03/44167381/target-hospitality-secures-five-year-lease-with-corecivic-for-dilley-facility-stock-gains" target="_blank" rel="noreferrer noopener">Target Hospitality Secures Five-Year Lease With CoreCivic For Dilley Facility, Stock Gains</a></li>
</ul>
Photo by Ciara Kimsey via Shutterstock

Large Cap

Health Care

Contracts

General

TDOC

Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss

Telsey Advisory Group analyst Dana Telsey maintains Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) with a Outperform and maintains $340 price target.

BURL

Telsey Advisory Group Maintains Outperform on Burlington Stores, Maintains $340 Price Target

SVCO

Silvaco Group shares are trading lower. The company reported Q4 financial results.

Telsey Advisory Group analyst Joseph Feldman maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and maintains $73 price target.

Telsey Advisory Group Maintains Outperform on Kroger, Maintains $73 Price Target

CTOS

Custom Truck One Source shares are trading higher after Oppenheimer raised its price target on the stock from $5 to $6 and maintained its Outperform rating.

Macquarie analyst Paul Golding maintains United Parks &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>) with a Outperform and lowers the price target from $70 to $65.

PRKS

Macquarie Maintains Outperform on United Parks & Resorts, Lowers Price Target to $65

Trading Halt: Halt status updated at 11:25:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Teladoc Health shares are trading higher after the company announced a pharmacy integration agreement with Gifthealth for a GLP-1 self-pay option.

Macquarie analyst Paul Golding maintains Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) with a Outperform and raises the price target from $30 to $31.

NCLH

Macquarie Maintains Outperform on Norwegian Cruise Line, Raises Price Target to $31

TRML

Tourmaline Bio shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced a price target of $42.

Hims & Hers Health shares are trading lower following reports suggesting a federal judge ruled in favor of the FDA in the tirzepatide compounding case.

Macquarie analyst Paul Golding maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Outperform and raises the price target from $146 to $165.

Macquarie Maintains Outperform on Live Nation Entertainment, Raises Price Target to $165

HIPO

Hippo Holdings shares are trading higher following better-than-expected Q4 financial results.

Press Releases

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

Kuehn Law Encourages Investors of Akero Therapeutics, Inc. to Contact Law Firm

Legal

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Financing

Akero Therapeutics Announces Proposed Public Offering of Common Stock

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino's Pizza Corp. (NASDAQ: DPZ)

Earnings

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

CROX

EXTR

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Alkermes

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Biohaven

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Amicus Therapeutics

Immunovant

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Metsera

Nuvalent

PTC Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

TG Therapeutics

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

HC Wainwright & Co.

B of A Securities

Morgan Stanley

Citigroup

이 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 아케로 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>)의 주가는 회사가 <a href="https://www.benzinga.com//node/43231670" target="_blank" rel="noreferrer noopener">에프룩시퍼민(Efruxifermin)에 대한 SYMMETRY 2B상 연구</a>의 96주차 예비 결과를 보고한 후 주가는 106.57% 급등했다. 몇몇 애널리스트들이 <a href="https://www.benzinga.com/quote/akro/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 상향 조정</a>했다.
2. 서저리 파트너스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/43281237" target="_blank" rel="noreferrer noopener">베인 캐피탈 프라이빗 에쿼티로부터 비구속적 인수 제안을 받았다고 발표한 후 25.44% 상승</a>했다.
3. 플래그스타 파이낸셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>)의 주가가 24.40% 상승했다. 이는 회사가 <a href="https://www.benzinga.com//node/43330170" target="_blank" rel="noreferrer noopener">예상보다 좋은 재무 결과를 발표</a>한 후 바클레이즈의 애널리스트 자레드 쇼(Jared Shaw)가 비중 확대를 유지하고 <a href="https://www.benzinga.com/quote/flg/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 가격을 13달러에서 14달러로 상향 조정</a>했기 때문이다.
4. 넥스트랙커(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>)의 주가가 22.98% 상승했다. 이는 회사가 2025 회계연도 3분기 재무 실적이 예상보다 좋게 나타났고 가이던스를 상향 조정했다고 발표한 후 여러 애널리스트들이 <a href="https://www.benzinga.com//node/43319444" target="_blank" rel="noreferrer noopener">목표 주가를 수정</a>했기 때문이다.
5. 브라이트하우스 파이낸셜(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>)의 주가가 21.76% 상승했다. 이는 회사가 <a href="https://www.benzinga.com//node/43275032" target="_blank" rel="noreferrer noopener">잠재적 매각을 검토 중이라는 보고서</a> 이후 바클레이즈의 애널리스트 알렉스 스캇(Alex Scott)이 회사를 중립에서 비중 확대으로 상향 조정하고 <a href="https://www.benzinga.com/quote/bhf/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 가격을 52달러에서 85달러로 상향 조정</a>했기 때문이다.
6. 브링커 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>)의 주식이 21.72% 상승했다. 이는 회사가 2분기 실적이 예상보다 좋게 나타났고 여러 애널리스트들이 <a href="https://www.benzinga.com//node/43335877" target="_blank" rel="noreferrer noopener">가격 예측을 변경</a>했다고 발표한 후 발생한 일이다.
7. 힘스 &amp; 허스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>)의 주식이 20.76% 상승했다.
8. 오시코시 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>)의 주식이 19.38% 급등했다. 이는 회사가 4분기 실적을 예상보다 높게 발표하고 FY25 EPS 가이던스를 예상보다 높게 설정하며 <a href="https://www.benzinga.com//node/43331819" target="_blank" rel="noreferrer noopener">분기 배당금을 11% 인상</a>한 후 애널리스트들이 <a href="https://www.benzinga.com/quote/osk/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 상향 조정</a>했기 때문이다.
9. 킹소프트 클라우드 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>)의 주식이 16.50% 상승했다. 이는 설날, 최근 중국의 AI 발전 및 정부의 시장 부양 노력으로 인한 것으로 보인다.
10. 비아비 솔루션스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>)의 주식이 14.78% 상승했다. 이는 회사가 <a href="https://www.benzinga.com//node/43353084" target="_blank" rel="noreferrer noopener">예상보다 좋은 2분기 재무 결과를 발표</a>한 후 발생한 일이다.
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%95%8C%EB%A6%AC%EB%B0%94%EB%B0%94-ibm-%EB%B0%8F-%EB%93%80%EC%98%A4%EB%A7%81%EA%B3%A0-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10/" target="_blank" rel="noopener">알리바바, IBM 및 듀오링고 지난주 최고 성과를 보여준 10개 대형주 중 일부 (1월 27일-1월 31일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%94%EB%B9%84%EB%94%94%EC%95%84-%ED%85%8C%EB%B0%94-%ED%8C%8C%EB%A7%88-%EB%B0%8F-ups-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%ED%95%98%EB%9D%BD%ED%95%9C-12%EA%B0%9C%EC%9D%98-%EB%8C%80%ED%98%95/" target="_blank" rel="noopener">엔비디아, 테바 파마 및 UPS 등 지난주 하락한 12개의 대형주 (1월 27일-1월 31일)</a></li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Akero Therapeutics

뉴스

에 대한 최신 뉴스 Akero Therapeutics (NASDAQ:AKRO) 주식

일요일, 2월 02, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌